Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Ex Input:
Paragraph: "Residents of some Baltimore neighborhoods are no better off than people living in impoverished North Korea and the violent West Bank, Bernie Sanders said during a campaign rally in Maryland ahead of that state's primary. ""Poverty in Baltimore, and around this country poverty is a death sentence,"" Sanders said April 24. He then laid out some rather unflattering and harsh comparisons: ""Fifteen neighborhoods in Baltimore have lower life expectancies than North Korea. Two of them have a higher infant mortality rate than the West Bank in Palestine. Baltimore teenagers between the ages of 15 and 19 face poorer health conditions and a worse economic outlook than those in distressed cities in Nigeria, India, China and South Africa. We are talking about the United States of America in the year 2016 a country in which the top 1/10th of 1 percent now owns almost as much wealth as the bottom 90 percent."" While it would be wrong to take Sanders' claim to mean that conditions overall are worse than Baltimore, we found that his specific comparisons are largely accurate. ""The comparisons fairly make the point that there are some parts of this rich country where conditions resemble those in much poorer countries,"" said Alan Berube, an expert on urban poverty at the Brookings Institution. ""This isn't isolated to Baltimore; there are neighborhoods in nearly every big U.S. city and metropolitan area, and many rural communities, that perform just as poorly on these outcomes."" Let's take Sanders' claims one by one. Life expectancy in North Korea The Sanders campaign referred us to a Washington Post article noting that 14 Baltimore neighborhoods had shorter life expectancies than North Korea in 2013. (The article originally said 15 but was corrected.) His number is slightly outdated. In 2014, the latest year where there's data on both places, the average life expectancy in North Korea was 69.81 years, according to the CIA World Factbook. That placed the impoverished dictatorship at No. 155 in longest lifespans out of 224 countries. The United States overall ranked at No. 42 with 79.56 years. Residents in 12 of Baltimore's 56 neighborhoods lived shorter lives, according to data from the Baltimore City Health Department provided to the Baltimore Neighborhood Indicators Alliance. That's not 15, but it's close. (For context, just five Baltimore neighborhoods have life expectancies higher than the U.S.national average, and four of them are relatively affluent and white.) Here's a map from the University of Maryland's Capital News Service that compares the life expectancies of Baltimore neighborhoods in 2013 to other places in the world: An important caveat: The city of Baltimore has a total population around 600,000 people while North Korea has a population 40 times that. That means fewer events in Baltimore neighborhood could swing the overall life expectancy of a neighborhood up or down. Infant mortality in the West Bank For this claim, the Sanders campaign referred us to a Vox article that said two neighborhoods in Baltimore Little Italy and Greenmount East had a higher rate of infant mortality than the West Bank, Honduras and Venezuela in 2013. But in his speech, Sanders only mentioned the West Bank. In 2014, 13.49 out of 1,000 babies died before their first birthday in the notorious conflict zone, according to the CIA's World Factbook. The West Bank places in the middle of the pack in infant mortality at No. 117 out of 224 countries. The United States, meanwhile, ranked at No. 169 with a rate of 6.17 deaths per 1,000. In 2014, 11 Baltimore neighborhoods had a higher rate than the West Bank. In Hilltop and Little Italy, at least 20 out of 1,000 infants died before their first birthday. That's not only higher than the West Bank, Honduras and Venezuela but also war-torn Syria and oppressive Uzbekistan. Teen health in distressed cities in developing countries Sanders claimed that ""Baltimore teenagers between the ages of 15 and 19 face poorer health conditions and a worse economic outlook than those in distressed cities in Nigeria, India, China and South Africa."" The Sanders campaign cited a Washington Post article by Johns Hopkins University researchers. ""Teenagers in Baltimore face poorer health and more negative outlooks than those in urban centers of Nigeria, India and China,"" they write. Contrary to what Sanders said, the work by theJohns Hopkins researchersdon't consider economic outlooks nor do they show Baltimore conditions being worse than South Africa's. Nonetheless, his broader point is accurate. The researchers published acomprehensive set of studies published in the Journal of Adolescent Health in 2014 thatcompared the well-being of teens in impoverished areas in Baltimore; Ibadan, Nigeria; Johannesburg, South Africa; New Delhi, India; and Shanghai, China. Baltimore teens reported the highest rates pregnancy and, after Johannesburg, the second highest rates of substance use, sexual and physical violence, and feeling unsafe in their community: Our ruling Sanders presented a series of comparisons showing that conditions in some parts of Baltimore rivaled that of ""the West Bank in Palestine,"" ""North Korea,"" and ""distressed cities in Nigeria, India, China and South Africa. Some of Sanders' figures need to be updated, but the gist of his specific comparisons are accurate: 12 Baltimore neighborhoods have a lower life expectancy than North Korea; 11 have a higher infant mortality rate than the West Bank; and research shows health conditions are worse for poor teens than in Baltimore than in Ibadan, New Delhi and Shanghai." Claim: "Bernie Sanders Says an array of statistics show that conditions in some parts of Baltimore rival that of ""the West Bank in Palestine,"" ""North Korea,"" and ""distressed cities in Nigeria, India, China and South Africa."

Ex Output:
"Sanders presented a series of comparisons showing that conditions in some parts of Baltimore rivaled that of ""the West Bank in Palestine,"" ""North Korea,"" and ""distressed cities in Nigeria, India, China and South Africa. Some of Sanders' figures need to be updated, but the gist of his specific comparisons are accurate: 12 Baltimore neighborhoods have a lower life expectancy than North Korea; 11 have a higher infant mortality rate than the West Bank; and research shows health conditions are worse for poor teens than in Baltimore than in Ibadan, New Delhi and Shanghai."

Ex Input:
Paragraph: A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville The GlaxoSmithKline Plc vaccine Rotarix fights infection with the rotavirus, which causes about 55,000 hospitalizations in U.S. children each year and kills more than 600,000 children worldwide, mostly in developing countries. Rotarix already is approved in more than 100 other countries throughout the world. The vaccine competes with Merck & Co Inc's rotavirus vaccine called RotaTeq. Without vaccination, nearly every child in the United States likely would be infected at least once with rotavirus by age five, the Food and Drug Administration said. In studies of more than 24,000 infants, Rotarix prevented severe and mild cases of rotavirus-caused diarrhea and vomiting during the first two years of life. "This vaccine provides another option to combat and reduce a potentially severe illness that affects so many children," Dr. Jesse Goodman, director of the FDA's Center for Biologics Evaluation and Research, said in a statement announcing the Rotarix approval. The most common reactions reported during clinical trials were fussiness, irritability, cough, runny nose, fever, loss of appetite and vomiting, the FDA said. An earlier oral rotavirus vaccine sold by Wyeth was pulled from the market in 1999 after it was linked to a rare, life-threatening type of bowel obstruction known as intussusception. In a Glaxo study of more than 63,000 infants, there was no increase in the problem compared with a placebo. Higher rates of convulsion and pneumonia-related deaths were seen in Rotarix patients in that study but not in other Glaxo trials. "Although the FDA has concluded that the available data do not establish that these events are related to the vaccine, the agency has requested the manufacturer to conduct post-marketing safety studies involving more than 40,000 infants to provide additional safety information," the FDA said. Glaxo said Rotarix "will offer protection against the most commonly circulating rotavirus types in the U.S. and allow infants to complete the vaccination series by four months of age." Rotarix, which is a liquid, is given in two doses to infants from six to 24 weeks of age, the FDA said. Merck's RotaTeq vaccine is administered in three doses from ages six weeks to 32 weeks. Sales of Rotarix were $182 million in 2007 and are expected to rise with approval in the large U.S. market. The vaccine will be commercially available in the United States in the second half of the year, Glaxo said. Also on Thursday, researchers reported that Rotarix provided protection for up to two years in a study of infants from 10 Latin American countries. The Glaxo-funded trial of more than 15,000 infants found severe diarrhea from rotavirus in 0.4 percent of children given the vaccine, compared with 2.3 percent in the placebo group. Results were published in the Lancet medical journal. The arrival of a new generation of oral vaccines against the disease has been welcomed by health-care workers, but some experts caution against assuming the vaccines will work equally well in all countries. In a commentary in the Lancet, Australian pediatric experts Keith Grimwood and Carl Kirkwood noted Rotarix was more effective in European trials than in middle-income Latin American countries. The World Health Organization "is awaiting efficacy data from low-income countries of Africa and Asia, where much greater strain diversity exists and where 413,000 deaths occur every year compared with 15,000 in Latin America and 200 in Europe," Grimwood and Kirkwood wrote. Claim: Glaxo wins FDA clearance for rotavirus vaccine.

Ex Output:
A second oral vaccine to prevent a leading cause of severe diarrhea in infants won approval from U.S. health officials on Thursday.

Ex Input:
Paragraph: It is not the first time drugmakers have clashed with Pretoria. A decade ago the industry was forced to climb down in a bruising battle with South Africa over AIDS drugs patents and access to generics. The latest fight reflects tension between an industry that wants to protect its intellectual property, even as it pushes further into emerging markets, and governments from India to Brazil that are determined to increase patients' access to life-saving treatments. South Africa is in the final stages of implementing a new law that would allow generic drugmakers to produce cut-price copies of patented medicines and make it harder for firms to register and roll over patents. Global drugmakers have drawn up a $600,000 publicity campaign to mobilize local and overseas opposition to the intellectual property (IP) changes, according to a document written by a drugs industry lobby group and seen by Reuters. Minister of Health Aaron Motsoaledi on Friday lashed out at drugmakers, saying their campaign was aimed at turning South Africans against the government. "It's a conspiracy of satanic magnitude," he said. "This document can sentence many South Africans to death. This is a plan for genocide." The ruling African National Congress is looking to cut healthcare costs as it grapples with the world's heaviest HIV/AIDS caseloads and its biggest treatment program. The new law is expected to reduce medicine prices and open up a fledgling generic drug industry dominated by Aspen Pharmacare and Adcock Ingram. The policy would also close a loophole known as "ever-greening" that allows a drugmaker to make minor changes to an existing drug or discover a new use for it, and then register it as a totally new find. Healthcare activists say South Africa's track record of approving drug patents - in 2008 it granted more than 2,400 patents compared with fewer than 300 in six years in Brazil - shows the need for reform. The document - prepared by U.S. consultancy Public Affairs Engagement for industry lobby Innovative Pharmaceutical Association South Africa (IPASA) - outlines a plan to delay the reform at least until after South Africa's elections in early May by suggesting the new law would be politically damaging. "The world cares that South Africa is proposing to take a wrong turn in economic policy by weakening IP protections. And by cares, we mean both expresses compassionate concern and will take action by reducing investment," the document reads. IPASA members include drugmakers such as Sanofi, Baxter International, Pfizer and Novartis. IPASA spokeswoman Val Beaumont confirmed the authenticity of the document but said the proposals were still under consideration. "No part of those proposals have been accepted. No part of that document has been implemented," she told Reuters. The industry could now ditch the campaign - which it dubbed "Almost Political" - because the leaked document has likely weakened its negotiating position. Under current South African IP law, pharmaceutical companies are able to register drugs as new without being checked for their novelty. Claim: South Africa slams Big Pharma in generic drugs row.

Ex Output:
South Africa on Friday slammed global drug firms over a covert campaign against its planned overhaul of intellectual property laws to favor cheaper generic drugs, accusing pharmaceutical companies of a "satanic" plot to commit "genocide".